GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (FRA:0L8) » Definitions » Net Issuance of Preferred Stock

Lantheus Holdings (FRA:0L8) Net Issuance of Preferred Stock : €0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Lantheus Holdings's net issuance of preferred for the three months ended in Mar. 2024 was €0 Mil. The number is 0, which means that Lantheus Holdings has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Lantheus Holdings's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was €0 Mil.


Lantheus Holdings Net Issuance of Preferred Stock Historical Data

The historical data trend for Lantheus Holdings's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Net Issuance of Preferred Stock Chart

Lantheus Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lantheus Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lantheus Holdings Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantheus Holdings Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings (FRA:0L8) Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings (FRA:0L8) Headlines

No Headlines